EPAC Earnings

EPAC reported its FY2026Q1 earnings on 2025-12-17, showcasing a revenue of 144.00M against an estimate of 146.00M, resulting in a -1.16% surprise. The EPS was 0.36, surpassing the expected 0.38 by -5.26% . The stock experienced a -8.79% price change on the earnings day and a 1.5% change over the next five days, reflecting market reactions to the results.

Following EPAC's FY2026Q1 earnings announcement on 2025-12-17, the stock price moved by -8.79% on the day of the release. Over the subsequent five days, it saw a 1.50% change. Historically, EPAC's stock price tends to shift by an average of -0.41% in the 10 days leading up to earnings and -1.16% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate EPAC’s annual revenue to reach 148.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -0.93% and EPS estimates Revise Downward by -2.38% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between EPAC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Downward by -0.93%, while EPS estimates moved Revise Downward by -2.38% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, EPAC's stock price typically moves by -0.41% in the 10 days before its earnings and -1.16% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.00 and revenue of 148.00M.

The earnings call revealed positive aspects such as a shift to higher-margin services, strong R&D investment, and solid growth in Cortland Biomedical. The Q&A section highlighted strategic moves to enhance service value and product innovation, despite some market softness and unclear details on certain initiatives. The company's positive guidance, increase in free cash flow, and low net debt-to-EBITDA ratio further support a positive outlook. Given the market cap, the stock price is likely to react positively, but not overwhelmingly, resulting in a 'Positive' prediction (2% to 8%).